YIL102C Antibody

What is YIL102C-A and why is it significant for antibody-based research?

YIL102C-A is a protein found in the yeast Saccharomyces cerevisiae that directly interacts with Dpm1 and influences its dolichyl phosphate mannose (DPM) synthase activity. Its significance stems from being identified as a functional homolog of the DPMII subunit (DPM2) found in other organisms such as Trichoderma reesei and humans. The protein is essential for yeast viability, as deletion of the YIL102C-A gene results in lethality, a phenotype that can be reversed by introducing the dpm2 gene from T. reesei . Antibodies against YIL102C-A provide valuable tools for studying protein-protein interactions, particularly in glycosylation pathways and membrane protein complexes. Due to its interaction with glucosylphosphatidylinositol-N-acetylglucosaminyl transferase (GPI-GnT), similar to DPM2 in human cells, YIL102C-A antibodies are essential for comparative studies of glycosylation machinery across species .

How does the function of YIL102C-A differ from its homologs in other organisms?

While DPM synthase operates as a complex of three proteins (Dpm1, Dpm2, and Dpm3) in most organisms, S. cerevisiae was previously thought to utilize only a single Dpm1 protein. The C-terminal transmembrane domain of Dpm1 performs the function of Dpm3 in S. cerevisiae. Recent research has demonstrated that YIL102C-A serves the regulatory function of Dpm2, which was previously believed to be absent in S. cerevisiae . The protein's role appears to be conserved across species despite structural differences, as it interacts with both Dpm1 and GPI-GnT complexes in a manner similar to DPM2 in human cells . This functional conservation despite potential structural differences makes antibodies against these proteins valuable for comparative studies across species and for understanding the evolution of glycosylation machinery.

What are the primary applications of YIL102C-A antibodies in glycobiology research?

YIL102C-A antibodies serve several crucial functions in glycobiology research, including: (1) Detecting and quantifying YIL102C-A protein expression in wild-type and mutant yeast strains, (2) Confirming protein-protein interactions through co-immunoprecipitation of YIL102C-A with Dpm1 and components of the GPI-GnT complex, (3) Studying the subcellular localization of YIL102C-A through immunofluorescence or immunoelectron microscopy, and (4) Investigating the role of YIL102C-A in glycosylation pathways by tracking its association with other proteins in these pathways . These applications collectively enable researchers to elucidate the molecular mechanisms underlying dolichyl phosphate mannose synthesis and its connection to GPI anchor biosynthesis, which are fundamental processes in eukaryotic cells.

What immunoprecipitation protocols are most effective for studying YIL102C-A interactions with Dpm1?

For studying YIL102C-A interactions with Dpm1, researchers should implement a cross-linking immunoprecipitation protocol that preserves membrane protein complexes. Begin by harvesting yeast cells in mid-log phase and disrupting them using glass beads in a buffer containing 20 mM HEPES (pH 7.4), 150 mM NaCl, 1% digitonin or 1% Triton X-100, and a protease inhibitor cocktail. Prior to lysis, treat cells with membrane-permeable cross-linkers such as DSP (dithiobis[succinimidyl propionate]) at 1-2 mM for 30 minutes to stabilize transient protein-protein interactions . Following cell lysis, pre-clear the lysate with Protein A/G beads for 1 hour at 4°C, then incubate with anti-YIL102C-A antibody overnight. After washing the immunoprecipitated complexes thoroughly, analyze them by Western blotting using antibodies against Dpm1 and other potential interacting partners. This method has been shown to successfully capture the interaction between YIL102C-A and Dpm1, validating their functional relationship in the DPM synthase complex.

How can YIL102C-A antibodies be used to study the rescue of lethal phenotypes in deletion mutants?

To study the rescue of lethal phenotypes in YIL102C-A deletion mutants, researchers should employ a plasmid shuffling technique combined with immunological detection. First, create a heterozygous diploid strain (YIL102C-A/yil102c-a∆) and transform it with a URA3-marked plasmid containing wild-type YIL102C-A. After sporulation and tetrad dissection, select haploid yil102c-a∆ cells maintained by the URA3-marked plasmid . Subsequently, transform these cells with plasmids expressing either T. reesei dpm2 or other potential rescuing genes. To verify expression of the introduced genes, perform Western blotting using antibodies against YIL102C-A (for the wild-type control) or against epitope tags added to the heterologous proteins. Assess rescue by testing growth on 5-FOA medium, which selects for cells that have lost the URA3-marked YIL102C-A plasmid . Confirmation of protein expression using antibodies is critical for distinguishing between failed complementation due to lack of expression versus genuine functional incompatibility.

What are the best fixation and permeabilization methods for immunofluorescence studies using YIL102C-A antibodies?

For optimal immunofluorescence studies of YIL102C-A, which is a membrane-associated protein, a combination of paraformaldehyde and mild detergent permeabilization yields the best results. Begin by growing yeast cells to mid-log phase, then fix with 4% paraformaldehyde for 30 minutes at room temperature. After washing with PBS, treat cells with zymolyase (100 μg/ml) for 30 minutes at 30°C to create spheroplasts, which improves antibody penetration. Apply cells to poly-L-lysine-coated slides and permeabilize with 0.1% Triton X-100 for 5 minutes, followed by blocking with 3% BSA for 30 minutes. Incubate with primary anti-YIL102C-A antibody (1:100-1:500 dilution) overnight at 4°C, followed by fluorophore-conjugated secondary antibody incubation for 1 hour at room temperature. This method preserves the membrane architecture while allowing antibody access to epitopes. Counterstaining with DAPI and markers for subcellular compartments (such as the ER marker Kar2) enables precise localization of YIL102C-A relative to other cellular structures.

How can cross-species antibody reactivity be leveraged to study evolutionary conservation of DPM2/YIL102C-A function?

Exploiting cross-species antibody reactivity provides a powerful approach to studying the evolutionary conservation of DPM2/YIL102C-A function. Researchers should first evaluate antibody cross-reactivity using Western blotting against protein extracts from diverse fungal species and higher eukaryotes . Once cross-reactivity is established, implement a complementation assay where the YIL102C-A deletion in S. cerevisiae is rescued with orthologs from various species (T. reesei, C. albicans, humans, etc.). Use the cross-reactive antibodies to confirm expression of these orthologs and assess their ability to form complexes with S. cerevisiae Dpm1 through co-immunoprecipitation . Additionally, create chimeric proteins containing domains from different species' DPM2/YIL102C-A proteins to identify functionally conserved regions. Immunoprecipitation with domain-specific antibodies can then map interaction interfaces and determine which protein domains are essential for cross-species functionality. This approach has successfully demonstrated that the T. reesei dpm2 gene can reverse the lethal phenotype of YIL102C-A deletion, confirming functional conservation despite potential structural differences .

What approaches can be used to characterize post-translational modifications of YIL102C-A using antibody-based techniques?

Characterizing post-translational modifications (PTMs) of YIL102C-A requires a multi-faceted antibody-based approach. Begin by generating or acquiring antibodies that specifically recognize common PTMs (phosphorylation, ubiquitination, glycosylation) in addition to antibodies against the protein itself. Immunoprecipitate YIL102C-A from yeast cells grown under various conditions (different carbon sources, stress conditions, cell cycle stages) and analyze the precipitates using PTM-specific antibodies. For detailed mapping of modification sites, combine immunoprecipitation with mass spectrometry analysis. This can be achieved by purifying YIL102C-A using antibody-based affinity chromatography, followed by enzymatic digestion and LC-MS/MS analysis. Additionally, develop phospho-specific or other modification-specific antibodies once modification sites are identified, which enables monitoring of these modifications under different physiological conditions. This comprehensive approach will reveal how PTMs regulate YIL102C-A's interactions with Dpm1 and GPI-GnT, potentially uncovering regulatory mechanisms controlling glycosylation pathways.

How can proximity labeling be combined with YIL102C-A antibodies to map the extended interactome?

Proximity labeling combined with YIL102C-A antibodies offers a powerful approach to mapping the extended protein interactome beyond direct binding partners. Begin by creating a fusion protein of YIL102C-A with a promiscuous biotin ligase (BioID or TurboID) or peroxidase (APEX2). Express these fusion proteins in yeast using an appropriate vector system that maintains native expression levels . After activating the labeling enzyme with biotin or H₂O₂ (depending on the system used), isolate biotinylated proteins using streptavidin beads. Verify the presence of known interactors like Dpm1 and GPI-GnT components using specific antibodies to validate the approach . For comprehensive analysis, analyze the purified biotinylated proteins by mass spectrometry to identify all proteins in the vicinity of YIL102C-A. Compare the interactomes obtained under different growth conditions or in various mutant backgrounds to detect condition-specific interactions. This technique has been successfully applied to other membrane proteins in yeast and can reveal transient or weak interactions that might be missed by conventional immunoprecipitation approaches .

What are the most common causes of non-specific binding when using YIL102C-A antibodies, and how can they be minimized?

Non-specific binding when using YIL102C-A antibodies typically arises from several factors that can be systematically addressed. First, membrane proteins often exhibit hydrophobic surfaces that promote non-specific interactions. To mitigate this, optimize detergent concentration in lysis and washing buffers (start with 0.1% Triton X-100 or 0.5% digitonin) and include 5-10% glycerol to stabilize protein structure without promoting aggregation . Second, cross-reactivity with related proteins can be problematic due to sequence conservation among DPM family proteins. Address this by pre-absorbing antibodies with extracts from yil102c-a∆ strains complemented with heterologous genes or by using peptide competition assays to confirm specificity . Third, the yeast cell wall can trap antibodies, leading to high background in immunofluorescence. Ensure complete spheroplasting and optimize permeabilization conditions. Finally, increase blocking stringency by using a combination of 5% BSA and 5% normal serum from the secondary antibody's host species, and include 0.1-0.2% Tween-20 in all washing steps. Validating antibody specificity using multiple techniques (Western blotting, immunoprecipitation, and immunofluorescence) with appropriate controls is essential for confident interpretation of results.

How should researchers validate the specificity of commercially available and custom-made YIL102C-A antibodies?

A comprehensive validation strategy for YIL102C-A antibodies should include multiple complementary approaches. Begin with Western blot analysis comparing wild-type strains to those with YIL102C-A under regulatable promoters (e.g., GAL1 promoter) to confirm correlation between protein level changes and antibody signal intensity . For definitive validation, test the antibody against extracts from yil102c-a∆ strains complemented with YIL102C-A tagged with epitopes like HA or FLAG. The antibody should recognize the native protein while separate detection with anti-tag antibodies confirms the protein's identity. Peptide competition assays, where the antibody is pre-incubated with the immunizing peptide before use, should eliminate specific signals if the antibody is truly specific . Additionally, immunoprecipitate YIL102C-A and confirm its identity by mass spectrometry, which also helps identify potential cross-reactive proteins. For polyclonal antibodies, consider affinity purification against the immunizing antigen to improve specificity. Document antibody validation using the minimum reporting guidelines established by the International Working Group for Antibody Validation (IWGAV) to ensure reproducibility across laboratories.

What quality control parameters should be monitored when purifying and storing YIL102C-A antibodies for long-term research use?

Maintaining antibody quality for long-term research requires monitoring several key parameters throughout purification and storage. During purification, measure protein concentration using both absorbance at 280 nm and colorimetric assays (Bradford or BCA) to ensure accuracy. Assess antibody purity using SDS-PAGE with silver staining, aiming for >90% purity with distinct heavy and light chain bands at approximately 50 kDa and 25 kDa, respectively. Verify specificity using Western blotting against positive controls (wild-type yeast extracts) and negative controls (yil102c-a∆ complemented with heterologous genes) . Monitor functional activity through titration experiments to determine the optimal working concentration for each application. For storage, aliquot antibodies in small volumes (20-50 μl) to minimize freeze-thaw cycles, and store at -80°C for long-term preservation or at 4°C with 0.02% sodium azide for short-term use. Include 10-15% glycerol or 1% BSA as stabilizers. Establish a quality control program where antibody performance is periodically tested against reference standards to detect any deterioration. Document lot numbers, purification dates, and quality control results to maintain traceability throughout extended research projects.

How might YIL102C-A antibodies be used to investigate connections between glycosylation defects and protein quality control pathways?

YIL102C-A antibodies offer unique opportunities to investigate the intersection between glycosylation and protein quality control pathways. Researchers can employ co-immunoprecipitation studies using YIL102C-A antibodies to identify interactions with components of ER-associated degradation (ERAD) machinery and unfolded protein response (UPR) sensors under various stress conditions . Combine this with proximity labeling approaches to capture transient interactions that occur specifically when glycosylation is impaired. Design pulse-chase experiments with glycosylation inhibitors (tunicamycin, 2-deoxyglucose) followed by immunoprecipitation with YIL102C-A antibodies to track changes in protein associations during glycosylation stress . Additionally, create reporter substrates that depend on proper glycosylation for folding, and use YIL102C-A antibodies to monitor how modulation of YIL102C-A levels affects their processing and degradation. Recent studies with chaperone networks suggest that glycosylation defects trigger specific cellular stress responses that may be mediated through protein complexes involving YIL102C-A . Immunofluorescence studies using YIL102C-A antibodies can reveal stress-induced changes in localization patterns, potentially identifying new quality control compartments that form under glycosylation stress conditions.

What role might YIL102C-A play in the formation of biomolecular condensates, and how can antibodies help investigate this?

Recent research has highlighted the importance of biomolecular condensates in cellular organization, and YIL102C-A may participate in this phenomenon similarly to other AAA+ ATPases like Rvb1 and Rvb2, which have been demonstrated to form condensates under nutrient starvation . To investigate this possibility, researchers can employ YIL102C-A antibodies in live-cell imaging studies using techniques like lattice light-sheet microscopy combined with specific labeling methods. Perform immunofluorescence under various stress conditions (nutrient limitation, heat shock, oxidative stress) to detect potential redistribution of YIL102C-A into punctate structures characteristic of biomolecular condensates . Use antibodies in proximity ligation assays (PLA) to identify proteins that associate with YIL102C-A specifically within these condensate structures. For in vitro studies, purify YIL102C-A using antibody-based affinity chromatography and assess its ability to undergo liquid-liquid phase separation alone or in combination with interacting partners like Dpm1. Additionally, examine how post-translational modifications affect condensate formation by using modification-specific antibodies in combination with condensate-inducing conditions. This research direction could reveal new layers of regulation for glycosylation pathways through spatial reorganization of key components like YIL102C-A in response to cellular stresses.

How can advanced imaging techniques combined with YIL102C-A antibodies reveal the spatial organization of glycosylation machinery?

Advanced imaging techniques coupled with YIL102C-A antibodies can provide unprecedented insights into the spatial organization of glycosylation machinery. Super-resolution microscopy approaches such as STORM, PALM, or STED can overcome the diffraction limit to visualize the nanoscale distribution of YIL102C-A relative to other glycosylation components within the ER membrane . Implement multi-color imaging using YIL102C-A antibodies alongside markers for different ER subdomains to determine if glycosylation machinery is compartmentalized. Correlative light and electron microscopy (CLEM) can combine the specificity of immunofluorescence with the ultrastructural details from electron microscopy to precisely localize YIL102C-A within membrane architectures . Advances in expansion microscopy, where samples are physically expanded while maintaining relative protein positions, can be combined with YIL102C-A immunolabeling to achieve super-resolution-like images on conventional microscopes. For dynamic studies, develop approaches to label YIL102C-A antibody fragments for live-cell imaging, potentially through genetically encoded tags that allow specific labeling of intracellular proteins in living cells. Time-resolved imaging after various perturbations can reveal how the spatial organization of glycosylation machinery responds to cellular needs and stresses, providing insights into the regulation of these essential processes.